默克雪兰诺为新型免疫肿瘤药物 M7824 启动临床试验，该药物作为一种分子可以应对两种通路，在目前的癌症免疫治疗领域，它可能代表了一种进展。这种具有两种功能的免疫治疗药物是日前该公司更新的其研发目录...
Merck Serono start clinical trials for new drugs of tumor immune M7824. The drug as a molecular can deal with two pathways. In the field of cancer immunotherapy, it may on behalf of the progress. This has two functions of immune therapy is the company updated its research and development directory...
